Log in

NASDAQ:NVAX - Novavax Stock Price, Forecast & News

-0.22 (-2.77 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $7.72
50-Day Range
MA: $6.42
52-Week Range
Now: $7.72
Volume1.80 million shs
Average Volume4.60 million shs
Market Capitalization$247.97 million
P/E RatioN/A
Dividend YieldN/A
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:NVAX



Sales & Book Value

Annual Sales$34.29 million
Book Value($8.77) per share


Net Income$-184,750,000.00
Net Margins-940.32%


Market Cap$247.97 million
Next Earnings Date3/16/2020 (Estimated)

Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.

Novavax (NASDAQ:NVAX) Frequently Asked Questions

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

When did Novavax's stock split? How did Novavax's stock split work?

Novavax's stock reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.24. The biopharmaceutical company earned $2.51 million during the quarter, compared to analysts' expectations of $4.40 million. During the same quarter in the previous year, the business earned ($2.40) earnings per share. View Novavax's Earnings History.

When is Novavax's next earnings date?

Novavax is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Novavax.

What price target have analysts set for NVAX?

9 analysts have issued 12 month target prices for Novavax's shares. Their forecasts range from $7.00 to $27.50. On average, they anticipate Novavax's share price to reach $15.93 in the next year. This suggests a possible upside of 106.3% from the stock's current price. View Analyst Price Targets for Novavax.

What is the consensus analysts' recommendation for Novavax?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novavax.

What are Wall Street analysts saying about Novavax stock?

Here are some recent quotes from research analysts about Novavax stock:
  • 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (1/30/2020)
  • 2. HC Wainwright analysts commented, "We derived our price target of $12 using DCF methodology with a 30% discount rate, 2% terminal growth rate, and a clinical program probability-of-success of 72%. Risks to our investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, unproven commercialization strategy, failure of products to show sufficient differentiation in targeted therapeutic indications, patent expiry or invalidation, and potential to raise additional funds under poor market conditions." (7/1/2019)

Has Novavax been receiving favorable news coverage?

News stories about NVAX stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novavax earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for Novavax.

Who are some of Novavax's key competitors?

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Trevena (TRVN), Gilead Sciences (GILD), Ocular Therapeutix (OCUL) and Opko Health (OPK).

Who are Novavax's key executives?

Novavax's management team includes the folowing people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 71)
  • Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 59)
  • Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 65)
  • Ms. Erika S. Trahan, Sr. Mang. of Investor & PR

Who are Novavax's major shareholders?

Novavax's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.33%), Charles Schwab Investment Management Inc. (0.46%), Bank of New York Mellon Corp (0.40%), TSP Capital Management Group LLC (0.39%), Ladenburg Thalmann Financial Services Inc. (0.14%) and Virtu Financial LLC (0.13%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including Creative Planning, Bank of America Corp DE, Virtu Financial LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Sargent Investment Group LLC and Sargent Investment Group LLC. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino and Michael A Mcmanus Jr. View Insider Buying and Selling for Novavax.

Which institutional investors are buying Novavax stock?

NVAX stock was acquired by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, Ikarian Capital LLC, UBS Group AG, Raymond James & Associates, Ladenburg Thalmann Financial Services Inc., Charles Schwab Investment Management Inc., Barclays PLC and State Street Corp. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, John Trizzino, Rachel K King and Stanley C Erck. View Insider Buying and Selling for Novavax.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $7.72.

How big of a company is Novavax?

Novavax has a market capitalization of $247.97 million and generates $34.29 million in revenue each year. The biopharmaceutical company earns $-184,750,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis. Novavax employs 373 workers across the globe.View Additional Information About Novavax.

What is Novavax's official website?

The official website for Novavax is http://www.novavax.com/.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]

MarketBeat Community Rating for Novavax (NASDAQ NVAX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  719 (Vote Outperform)
Underperform Votes:  442 (Vote Underperform)
Total Votes:  1,161
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel